Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Valeant grosses $2.3bn via FOPO

Executive Summary

To help fund its $8.7bn acquisition of private eye health firm Bausch & Lomb Inc., Valeant Pharmaceuticals International Inc. grossed $2.3bn in a follow-on public offering of 27mm common shares (including the overallotment) at $85.00 each.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register